



Past, Present and Further Looking for Therapeutic Management of Pancreatic Ductal Adenocarcinoma

Guest Editors:

Dr. Gennaro Nappo

Pancreatic Surgery Unit,
Humanitas Clinical and Research
Center, Humanitas University
Department of Biomedical
Sciences, Rozzano, Milan, Italy

Dr. Niccola Funel

Cancer Pharmacology Lab, AIRC
Start-Up Unit, Fondazione Pisana
per la Scienza onlus, 56017 Pisa,
Italy

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editors

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) still represents one of the cancers with the poorest prognosis.

This Special Issue aims to evaluate all the novel therapeutic approaches for the management of PDAC (resectable, borderline-resectable, locally advanced and metastatic disease): pre-clinical and clinical studies focusing on this topic will be included in this Special Issue.

Dr. Gennaro Nappo

Dr. Niccola Funel

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)